AU Stock MarketDetailed Quotes

PAR Paradigm Biopharmaceuticals Ltd

Watchlist
  • 0.420
  • 0.0000.00%
20min DelayTrading Dec 12 16:00 AET
146.76MMarket Cap-2.10P/E (Static)

About Paradigm Biopharmaceuticals Ltd Company

Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.

Company Profile

SymbolPAR
Company NameParadigm Biopharmaceuticals Ltd
Founded2014
MarketASX
Employees50
Fiscal Year Ends06-30
Address500 Collins Street Level 15
CityMelbourne
CountryAustralia
Zip Code3000
Phone+61 396295566
Share RegistryAUTOMIC REGISTRY SERVICES Level 5, 126 Phillip Street, SYDNEY, NSW, AUSTRALIA, 2000 02 9698 5414

Company Executives

  • Name
  • Position
  • Salary
  • Paul Rennie
  • Executive Director,Managing Director,Executive Chairman
  • --
  • Amos Meltzer
  • Non-Executive Director
  • --
  • Matthew James Fry
  • Non-Executive Director
  • --
  • Donna Skerrett
  • Executive Director
  • --